demonstrate that, contrary to current dogma, a significant part of the dermal lymphatic vasculature forms independent of Tie2 lineage venous-derived LECs.
Methods
Detailed Methods section is available in the Online Data Supplement.
Results

Region-Specific Differences in the Development of the Lymphatic Vessels in the Skin
To visualize dermal lymphatic vessel formation, we used the Vegfr3-lacZ reporter mice (Vegfr3 lz ). Consistent with previous data, we observed that the first lymphatic vessel sprouts reaching the skin emanated from the JLS at embryonic day (E) 12.5 ( Figure 1A 
, where vessels from contralateral sides anastamose by E17.5 (Online Figure IB) . Notably, dermal lymphatic vessels at the lumbar region seemed to develop independently from subcutaneous lymphatic vessels until E17.5 when connections between the 2 networks were formed (Online Figure IB) . The latter developed along major arteries and veins, whereas superficial dermal lymphatic vessels did not show an apparent alignment with blood vessels (Online Figure IB , data not shown). These results suggest that lymphatic vessels in different regions of the skin (cervical versus lumbar, dermis versus subcutis) develop via different mechanisms. In particular, emergence of LEC clusters without connection to vessel sprouts from the JLS suggests a novel mechanism of vessel formation and potentially a different cellular origin.
We next analyzed the expression of Prox1, the first known marker of differentiated LECs, 8 and the established lymphatic markers Nrp2, LYVE-1, and VEGFR3 in the dermal vasculature. Immunofluorescence analysis of lumbar skin from E13.5 Prox1-green fluorescent protein (GFP) embryos confirmed the presence of a discontinuous network and isolated clusters of GFP and Nrp2-positive LECs ( Figure 1D ). Some clusters were interconnected via long membrane protrusions, whereas others were isolated ( Figure 1D ; Online Movies I and II). Immunofluorescence for Prox1 similarly highlighted the Nrp2 + LEC clusters ( Figure 1D) . Surprisingly, most LEC clusters appeared LYVE-1 − , whereas developing vessels showed a weak LYVE-1 immunoreactivity ( Figure 1E ). Analysis of Vegfr3-GFP reporter embryos allowed visualization of isolated GFP + LECs already at E11.5 ( Figure 1F ).
Formation of Lymphatic Vessels in the Lumbar Skin Is Independent of Tie2 Lineage Venous-derived LECs
To investigate the origin of dermal lymphatic vessels, we used Cre/loxP-based lineage tracing. A transgenic mouse line expressing Cre recombinase under the control of the (blood) endothelial/hematopoietic-specific Tie2 promoter was crossed with the R26-mTmG double reporter line to allow irreversible marking of Tie2-expressing cells and their descendants with GFP, whereas all other cell types express the red fluorescent protein Tomato (Figure 2A (Figure 2A ). At E9 ≥89% of the LYVE-1 + ECs expressed GFP, increasing to ≥95% at E10 and E11, indicating efficient targeting by the Tie2-Cre transgene ( Figure 2B ; Online Figure IIA) . LYVE-1 − ECs, including LEC progenitors generated from the superficial venous plexus, 6 also showed highly efficient Tie2-Cre-mediated recombination at E11 (98.8±0.2%
[n=4]; Online Figure IIB) . A major proportion of ECs were also Tomato + at E9 and E10 ( Figure 2B ), because of perdurance of Tomato protein after Cre recombination that results in doublemarker expression. 9 Immunofluorescence analysis of E10.5 Tie2-Cre;R26-mTmG embryos further revealed GFP + cardinal veins ( Figure 2C ), which provide a source of LECs. 2 Consistent with this, JLSs of E12.5 Tie2-Cre;R26-mTmG embryos also showed efficient Cre recombination ( Figure 2D ; Online Figure IIC) .
We next assessed the contribution of venous-derived cells to dermal lymphatic vessels at E12.5, when the first LEC clusters emerge, and at E15.5, when lymphatic sprouts reach the dorsal midline area ( Figure 2E Figure  IIB ) and blood endothelial cells at E13 (Figure 2H ), at the stage of LEC cluster emergence, showed efficient targeting by the Tie2 transgene (98.1±0.4% at E11; n=3 and 99.4±0.7% at E13; n=8), thus excluding these cells as the origin of dermal LECs.
We next sought functional evidence for the nonvenous origin of dermal lymphatic vessels by deleting Prox1, the master regulator of LEC fate, 10 in blood endothelia using a conditional In agreement with previous data, 2 we indeed found that E14.5 Prox1 flox/flox ;Tie2-Cre embryos showed subcutaneous edema and failure of lymphatic vessel formation in the cervical skin ( Figure 3A ; Online Figure IVA ). However, we observed bloodfilled dermal lymphatic vessels and isolated LEC clusters in the lumbar skin ( Figure 3A ). Most LEC clusters were not targeted by the Tie2-Cre transgene and thus expressed Prox1 in the mutant embryos (Online Figure IVB ). These data demonstrate that the formation of lymphatic vessels in the lumbar skin is independent of Tie2 lineage venous-derived LECs. Most lymphatic structures were however lost in Prox1 flox/flox ;Tie2-Cre skin by E17.5 (Online Figure IVC) , likely because of progressive induction of Tie2 in the dermal lymphatic vasculature (Online Figure IID , data not shown) and consequent loss of Prox1 that is required for lymphatic vessel maintenance.
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Tracing of Prox1-Expressing Cells Suggests Continuous LEC Differentiation During Dermal Lymphatic Vessel Formation
To further investigate the origin of the dermal lymphatic vasculature, we used a tamoxifen-inducible Cre line to allow genetic labeling of cells expressing Prox1 (Online Figure V) . In contrast to a previous report, 2 we found that injection of 4-OHT to pregnant females at E10.5 or E11.5 led to a nearly complete absence of GFP + LECs in the skin (Online Figure VIA and VIB) and JLS (data not shown). It was possible that cells were not labeled because of continuous LEC differentiation between E10 and E12 2 and a short <24-hour time-window of 4-hydroxytamoxifen (4-OHT) activity in our study, in comparison with the longer period of activity after administration with tamoxifen in the previous study 2 Taken together, our data demonstrate the existence of a population of LEC progenitors that is distinct from venousderived LECs and contributes to the formation of the dermal lymphatic vasculature ( Figure 3C ).
Discussion
This study demonstrates that a large part of the superficial dermal lymphatic vasculature does not form via transdifferentiation and sprouting of Tie2 lineage venous ECs, which are currently thought to be the sole origin of the mammalian lymphatic vasculature. We found that lymphatic vessels of the dorsal midline and lumbar regions of the skin instead form from nonvenous-derived progenitors through a lymphvasculogenesis process involving assembly of LECs into clusters and their further coalescence to continuous vessel networks. The Prox1-CreER T2 lineage tracing defined E12.5-E14.5 as the critical time-window when nonvenous-derived LEC progenitors most actively incorporate into dermal lymphatic vessels, which is in agreement with the rapid emergence of these vessels at around E13.5.
The embryonic origin of lymphatic vessels has been controversial until recently. Genetic lineage tracing experiments in mouse and real-time imaging in zebrafish confirmed Sabin's theory on the venous origin of lymphatic vessels.
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These experiments did not, however, exclude the existence of alternative sources of LECs. Earlier observations interestingly showed that avian lymphatic vasculature has a dual origin, with JLSs originating from veins and superficial dermal lymphatic vessels from an unidentified nonvenous-derived precursors of mesodermal origin. 5 Together with our findings, this suggests evolutionarily conserved origins of LECs and mechanisms of lymphatic vessel formation.
Given the distinct origins, molecular mechanisms regulating lymphatic vessel formation in different regions of the skin are likely different. To understand these mechanisms, it is now of critical importance to first clarify the cell of origin of dermal LECs and identify their potential contribution to lymphatic vessels in other organs. Here, we excluded Tie2 lineage endothelial/hematopoietic cells and Vav lineage definitive hematopoietic cells as the source of dermal LECs. Interestingly, our recent study identified hemogenic endothelium-derived cells as an alternative nonvenous origin of lymphatic vessels in the mesentery. 13 However, the origin of nonvenous-derived LECs in the skin and mesentery seems to be different because, unlike dermal LECs, mesenteric LECs are derived from Tie2-lineage cells (unpublished data). Additional cell-type-specific lineage tracing experiments are required to identify the cellular source of nonvenous-derived LEC progenitors, which will allow further studies on their potential therapeutic use for lymphatic regeneration in disease in the future.
What Is Known?
• The mammalian lymphatic vasculature forms by sprouting from embryonic veins.
What New Information Does This Article Contribute?
• Part of the mammalian dermal lymphatic vasculature originates from an alternative nonvenous source.
• Nonvenous-derived lymphatic endothelial progenitors form vessels through a novel process defined as lymphvasculogenesis.
Endothelial cells forming the lymphatic vasculature have been described to originate through transdifferentiation and sprouting of venous endothelial cells. Alternative nonvenous sources of lymphatic endothelial cells have been suggested, although never demonstrated to exist in mammals. In this study, we reinvestigated the origin of the lymphatic vasculature by fate mapping. We found that lymphatic vessels in different regions of the skin have different origins and mechanisms of development. Vessels in the neck region form from veins through a sprouting process, as demonstrated in previous studies. However, in the lumbar region of the skin, lymphatic vessels develop from an alternative nonvenous source via a different process that we define as lymphvasculogenesis. Our data provide fundamental novel insight into the mechanism of lymphatic vessel formation by demonstrating the existence of a previously unknown lymphatic endothelial cell progenitor. Identification and characterization of the nonvenous lymphatic endothelial cell progenitors will allow further studies on their potential therapeutic use for lymphatic regeneration in disease in the future. 
SUPPLEMENTAL MATERIAL Detailed Methods
Mice
R26-mTmG
CTGAACTGATGGCGAGCTCAGAC). Prox1-CreER
T2 mice were generated as described 11 and tested by timed matings with Cre reporter strain followed by 4-hydroxytamoxifen (4-OHT) administration for specificity and efficiency of Cre-mediated recombination. For embryonic induction, 4-OHT, dissolved in peanut oil (10 mg/ml), was administered to pregnant females by intraperitoneal injection at indicated developmental stages. For lineage tracing experiments, a single intraperitoneal injection of 2 mg of 4-OHT was used. Early postnatal mice were administered with a single intraperitoneal injection of 50 µg of 4-OHT, dissolved in Ethanol, at P1. At adult stages Cre recombination was induced by feeding mice with tamoxifen-containing diet (Harlan) for two weeks, or by subcutaneous implantation of 15 mg slow-release tamoxifen pellets for 3 weeks (Innovative Research of America). Staging of E9 and E10 embryos was done by counting somite pairs. Embryos harvested before 10 am were typically of stages Eday.0-Eday.25. For staging of embryos older than E11, the morning of vaginal plug detection was therefore considered as E0. All strains were maintained and analysed on C57BL/6J background except for Prox1 lz-neo-flox that was on a mixed C57BL/6J x CD-1 background. Experimental procedures were approved by the United Kingdom Home Office and the Uppsala Laboratory Animal Ethical Committee.
Immunofluorescense and X-Gal staining
For whole-mount immunostaining, tissue was fixed in 4% paraformaldehyde (PFA) for 2h at RT, permeabilised in 0.3% Triton-X100 in PBS (PBSTx) and blocked in PBSTx plus 3% milk. Primary antibodies were incubated at 4°C overnight in blocking buffer. After washing in PBSTx, the samples were incubated with fluorocrome-conjugated secondary antibodies in blocking PBSTx plus 1% milk, before further washing and mounting in Mowiol. For visualization of cardinal veins and lymph sacs, 150 µm vibratome cross sections of E10.5, E11.5 and E12.5 Tie2-Cre;R26-mTmG or Prox1 lz-neo-flox embryos were used for staining as described above. The following antibodies were used: rat antimouse LYVE-1 (R&D systems), rat anti-mouse PECAM-1 (BD), hamster anti-mouse PECAM-1 (Millipore), rabbit anti-human Prox1 (generated against human Prox1 C-terminus (567-737aa), Prox1-GST construct provided by Dr. T. Petrova, University of Lausanne), rabbit anti-GFP (Invitrogen), chicken anti-GFP (Abcam), rat anti-mouse Endomucin (Santa Cruz Biotechnology), hamster antimouse Podoplanin (Developmental Studies Hybridoma Bank), goat anti-mouse VEGFR-2, VEGFR-3 or Neuropilin-2 (all from R&D Systems), rat anti-mouse F4/80 and CD169b (both from AbD Serotec) or rat anti-mouse CD45 (BD). Secondary antibodies conjugated to DyLight 405, AF488, Cy3 or Cy5 were obtained from Jackson ImmunoResearch. Staining for β-galactosidase activity in the lymphatic vessels in Vegfr3 lz and Prox1 lz-neo-flox mice was done using the substrate X-gal (5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside) using standard protocols.
Flow cytometry
Embryonic back skin and whole embryos were harvested and the tissues were cut into smaller pieces for digestion in Collagenase IV (Life Technologies) 4 mg/ml (skin) or 2 mg/ml (embryos), and DNase I (Roche) 0.2 mg/ml in PBS with 10% FBS at 37 °C under constant rotation for 8-20 min. Digests were quenched by adding 2 mM EDTA and filtered through a 70 µm nylon filter (BD Biosciences). Cells were washed with FACS buffer (PBS, 0.5% FBS, 2 mM EDTA) and immediately processed for staining in 96 well plates. Fc receptor binding was blocked by rat-anti mouse CD16/CD32 (93) (eBioscience). Skin samples were stained with anti-CD31/PECAM-1 (390) PE-Cy7, anti-LYVE-1 (ALY7) eF660 (E13 and E14), rat-anti podoplanin (PDPN) eF660 (eBio8. For analysis of Prox1-GFP + macrophages (Online Figure VIIIB) , back skin from E17.5 Prox1-GFP embryos was cut into small pieces and digested in Collagenase IV (10 mg/ml) for 30-45 minutes at 37°C, followed by passage through a 70 µm cell strainer (BD Falcon). Erythrocytes were lysed using RBC lysis buffer (eBioscience) for 5 minutes at RT. Single cell suspensions were incubated with rat anti-mouse CD45 (BD Pharmigen) and rat anti-mouse F4/80 (AbD Serotec) for 15 minutes followed by incubation with goat anti-rat AF647 (Invitrogen). Samples were analysed on a LSR II Analyser (BD Biosciences) and data analysis was done using FlowJo version 9.4.10.
Image acquisition
All confocal images except Figure 2G Table I . Stereomicroscope images of tissues were acquired with Leica MZ16F fluorescence microscope equipped with Leica DFC420C camera and Leica Microsystems software.
Quantification and image processing
Quantification of GFP + vessels in the Prox1-CreER T2 lineage tracing experiment was done using MetaMorph (Molecular Devices) software. Each skin was divided into two halves along the dorsal midline, which were further divided into four regions from lateral (a) to medial (d), as depicted in Online Figure VIB . In each region lymphatic vessels were selected based on positive Nrp2 staining as a region of interest (ROI) and the % of GFP staining over LYVE-1/Nrp2 staining on maximum intensity projection images was measured. Results are shown as mean ± SEM. 3D reconstruction and surface rendering movies of an isolated Nrp2 + LEC cluster were created from z-stack confocal images using Imaris (Bitplane Scientific Software).
Analysis of serum levels of the active 4-OHT metabolite
A single dose of 4-OHT or Tamoxifen was administered to C57BL/6J females (age = 10-11 weeks, weight = 20.1±1.5 g). 200 µl of blood was collected from the tail vein at different time points (6 h, 12 h, 24 h, 36 h, 48 h and 72 h). A maximum of three blood samples were taken from each mouse. Extraction of serum, sample preparation and analysis was performed following the protocol described in 12 .
Supplemental Figures and Figure Legends
Online Figure I . Visualisation of the developing dermal lymphatic vasculature by X-Gal staining of Vegfr3 lz embryos. (A) Lateral and dorsal views of E12.5, E13.5 and E15.5 embryos showing sprouting from the JLS in the cervical/thoracic regions and emergence of discontinuous network of vessels and isolated cell clusters in the lateral skin at the lumbar level and in the dorsal midline. Panels showing lateral view of E12.5 and E13.5 embryos are also shown in Figure 1A . Asterisks indicate the level of forelimbs. Arrowhead points to a subcutaneous lymphatic vessel (sc). Weak X-Gal staining can be observed in blood vessels. (B) Visualization of superficial and subcutaneous dermal lymphatic vessels in Vegfr3 lz embryos at E13.5 and E17.5. Subcutaneous vessels in the cervical/thoracic and sacral region connect to the superficial network of sprouting vessels (arrowheads) while in lumbar skin the two networks form separately and establish connections at E17.5 (arrows). Boxed area showing subcutaneous lymphatic vessels forming connections to the superficial lymphatic capillaries in the lumbar region is magnified on the right. 
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